Oncology innovation: The human cost of keeping pace with advances in cancer care

New research from Inizio Evoke explores the growing complexity of oncology innovation and how pharmaceutical companies can better support healthcare professionals (HCPs). 

The pace of oncology innovation is transforming cancer care. From breakthrough therapies to advances in precision medicine, scientific progress is creating new opportunities for patients. Yet translating these advances into clinical practice is becoming increasingly complex. 

A new white paper, authored by Maria Dzialo, PhD, Associate Director, Medical Strategy, Inizio Evoke, Chasing the Fourth Wave: The human cost of keeping pace, explores the hidden pressures facing oncologists, drawing on research conducted across six countries. 

How is oncology innovation increasing pressure on oncologists? 

• 71% of oncologists say the effort required to stay current with advances and translate them into treatment decisions has increased over the past five years. 
• 56% report that keeping pace extends into their personal time or creates additional pressure. 
• 81% report rapidly implementing relevant advances in their own practice, compared with 54% across the wider healthcare system. 

The findings highlight a critical opportunity for the pharmaceutical industry: supporting innovation isn’t just about delivering more information, but making scientific progress easier to navigate, understand, and implement. 

How can pharmaceutical companies support oncologists in keeping pace with innovation? 

By combining scientific expertise, human understanding, and connected capabilities, Inizio helps life sciences organizations navigate complexity and turn innovation into meaningful impact. 

Discover what these findings mean for the future of oncology engagement. Read the full white paper here.